Image

A Study to Assess NEU-411 in Healthy Participants

Recruiting
18 - 80 years of age
Both
Phase 1

Powered by AI

Overview

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose (SAD), food effect (FE),multiple ascending dose (MAD), of orally administered NEU-411 in healthy subjects

Description

Up to five (5) single-ascending oral doses will be administered to 40 healthy adult male or female subjects (aged 18-80 years, inclusive). Escalation to the next higher dose level may occur only after evaluation of the safety and PK results of the previous dose level (at least 6 evaluable subjects). Within each cohort, 6 subjects will receive one dose of NEU-411, and 2 subjects will receive one dose of matching placebo. Dose levels may be revised based on available safety and PK data.

Food effect will evaluate approximately 8 subjects in a fasted versus fed state.

Multiple ascending oral doses will be administered up to 24 healthy subjects (aged 18 - 80 years, inclusive) in 3 sequential dosing groups (8 subjects in each dosing group). Six (6) subjects will receive NEU-411 and two (2) subjects will receive matching placebo in each dosing group (cohort) for 7 days. Escalation to the next higher dose level may occur only after evaluation of the safety and PK results of the previous dose level (at least 6 evaluable subjects). Dose levels may be revised based on available safety and PD data.

Multiple oral dosing will be administered in up to 39 healthy subjects in 3 sequential dosing groups (13 subjects across 3 dosing groups) over 28 days.

Eligibility

Inclusion Criteria:

  • Subjects for standard cohorts must be 18-80 years, inclusive, at the time of signing the informed consent;
  • Subjects who are in good general health with no clinically relevant abnormalities based on the medical history, physical examinations, neurological examinations, clinical laboratory evaluations (hematology and clinical chemistry)
  • Subjects who have a body mass index (BMI) of 18-32 kg/m2(inclusive);
  • Male subjects are eligible to participate if they are rendered surgically sterile (at least 6 months), or agree to the following during the study and for at least 30 days after the last dose of study drug:
  • Refrain from donating sperm;

AND, either:

        Be abstinent from heterosexual intercourse as their preferred and usual lifestyle
        (abstinent on a long term and persistent basis) and agree to remain abstinent; OR Agree to
        use a male condom (contraception/barrier) and should also be advised of the benefit for a
        female partner to use an acceptable, highly effective method of contraception as a condom
        may break or leak when having sexual intercourse;
        • Female subjects are eligible to participate if they are not pregnant or breastfeeding,
        subject to one of the following:
          -  Women of childbearing potential (WOCBP), defined as women physiologically capable of
             becoming pregnant, must have a negative serum pregnancy test at the Screening visit
             and a negative urine pregnancy test on Day -1; WOCBP must agree to use an acceptable,
             highly effective contraceptive method from Screening until 30 days after the last dose
             of study treatment (see Section 11.3); OR
          -  Menopausal women must have an elevated serum follicle-stimulating hormone level (FSH)
             level at Screening; if the FSH is not elevated, they are considered to be of
             childbearing potential (unless permanently sterile) and must have a negative serum
             pregnancy test at Screening and a negative urine pregnancy test on Day -1
        Exclusion Criteria:
          -  History of clinically significant hematological, renal, pancreatic, gastrointestinal,
             hepatic, cardiovascular, metabolic, endocrine, immunological, allergic disease, or
             other major disorders
          -  History of clinically significant abnormal chest x-ray
          -  Clinically significant neurologic disorder
          -  Contraindications to undergo a lumbar puncture (only for subjects participating in the
             MAD)

Study details

Healthy

NCT05755191

Neuron23 Inc.

25 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.